Management of Early-Stage Resected Non-Small Cell Lung Cancer: Consensus Statement of the Lung cancer Consortium

Ahmed Allehebi (Oncology Department King Faisal Specialist Hospital & Research Center – Jeddah, Saudi Arabia), Khaled Al Kattan (Dean College of Medicine, Al Faisal University, King Faisal Specialist Hospital & Research Center – Riyadh, Saudi Arabia), Mashael Al Rujaib (Radiology Department, King Faisal Specialist Hospital & Research Center – Riyadh, Saudi Arabia), Fouad Al Dayel (Pathology Department, King Faisal Specialist Hospital & Research Center – Riyadh, Saudi Arabia), Edward Black (Thoracic surgery, SSMC-Mayo Partnership, Khalifa University, UAE), Mervat Mahrous (Oncology Department, Prince Sultan Military Medical City, Riyadh), Muath AlNassar (Oncology Department, Kuwait Cancer Control Center), Hamed Al Hussaini (Oncology Department King Faisal Specialist Hospital & Research Center – Riyadh, Saudi Arabia), Abdullah Al Twairgi (Oncology department, King Fahad Medical City, Riyadh), Nafisa Abdelhafeiz (Oncology Department, King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia), Ameen Al Omair (Radiation oncology, King Faisal Specialist Hospital & Research Center – Riyadh, Saudi Arabia), Salem Al Shehri (Radiation Oncology, King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia), Humaid O. Al-Shamsi (Department of Oncology and Innovation and Research Center, Burjeel cancer institute Abu Dhabi, College of Oncology Society – Dubai, College of Medicine, University of Sharjah, UAE), Abdul Rahman Jazieh (College of Medicine, Alfaisal University, Riyadh, Saudi Arabia, Cincinnati Cancer Advisors, Cincinnati, OH, USA)

Background
Management of early-stage non-small cell lung cancer (ES-NSCLC) has evolved over the last few years especially in terms of work-up and the use of systemic therapy. This consensus statement was developed to present updated guidelines for the management of this disease.

Methods
Multidisciplinary team (MDT) of lung cancer experts convened to discuss a set of pertinent questions with importance relevance to the management of ES-NSCLC. ES-NSCLC includes stages I, II and resected stage III. The experts included consultants in chest imaging, thoracic surgery, radiation oncology, and medical oncology. Questions were discussed in virtual meetings and then a written manuscript with supporting evidence was drafted, reviewed, and approved by the team members.

Results
The Consensus Statement included 9 questions addressing work-up and management of ES-NSCLC. Background information and literature review were presented for each question followed by specific recommendations to address the questions by oncology providers. The Statement was endorsed by various oncology societies in the Gulf region.

Conclusion:
The Consensus Statement serves as a guide for thoracic MDT members in the management of ES-NSCLC. Adaptation of these to the local setting is dictated usually by available resources and expertise, however, all efforts should be excreted to provide the optimal care to all patients whenever possible.

0 Comments
Submit a Comment

Your email address will not be published.

Share This
×

Talk to one of our Team Member

×